期刊文献+

罗格列酮对2型糖尿病患者的疗效观察 被引量:4

下载PDF
导出
摘要 目的观察罗格列酮对2型糖尿病患者的长期疗效和安全性。方法采用自身治疗前后对照法,对单用格列吡嗪或格列吡嗪加二甲双胍治疗,血糖控制欠佳的2型糖尿病患者59例加用罗格列酮治疗,进行3年随访,对血糖下降至空腹<5.5 mmol/l或餐后2 h<6.5 mmol/l的病人减少格列吡嗪7.5 mg/d,观察治疗前后血糖、糖化血红蛋白,空腹胰岛素,空腹C-肽,稳态模型胰岛素抵抗指数,高敏C反应蛋白水平及格列吡嗪用量。结果加服罗格列酮后,空腹血糖,餐后2 h血糖,糖化血红蛋白,空腹胰岛素,空腹C-肽,高敏C反应蛋白均明显下降,稳态模型胰岛素抵抗明显改善(P<0.01),格列吡嗪用量明显减少,至实验结束时共有28例患者完全停用格列吡嗪而血糖控制良好。结论单用格列吡嗪或格列吡嗪加二甲双胍疗效欠佳的2型糖尿病患者加服罗格列酮能长期有效控制血糖水平,减少或停用原联合应用的格列吡嗪。
出处 《南方医科大学学报》 CAS CSCD 北大核心 2008年第9期1738-1739,共2页 Journal of Southern Medical University
  • 相关文献

参考文献6

  • 1Croop LC, Pelkonen tL Koskimies S, et al. Secondary failure to treatment with Oral antidiabetic agents in non-insulin-dependent diabetes[J]. Diabetes Care, 1986, 9: 129-33.
  • 2Stumvoll M, Haring Hu, Glitazones: Clinical effects and molecular mechanisms[J]. Ann Med, 2002, 34(3):217-24.
  • 3Boden G, Cheng P, Mozzoli M, et al. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with tybe 2 diabetes [J]. Metabolism, 2003, 52: 753-9.
  • 4Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment oftybe 2 diabetes [J]. Diabetes Care, 1999, 22: 1568-77.
  • 5黄斌,罗琳,韩文群,谢雪,罗先策,魏东.马来酸罗格列酮对2型糖尿病患者糖脂代谢、胰岛素抵抗及血清炎症因子的影响[J].中国糖尿病杂志,2006,14(1):9-10. 被引量:27
  • 6Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone [J]. J Clin Endocrinol Metab, 2004, 89: 2728-35.

二级参考文献5

  • 1Wolffrenbuttel BHR,Gomist R,Squatrito S,et al.Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients.Diabetic Med,2000,17:40-47.
  • 2Pradhan A D,Manson J E,Nader R,et al.C-reactive protein,interleukin-6,and risk of developing type 2 diabetes mellitus.JAMA,2001,286:327-334.
  • 3Pickup JC,Crook MA.Is type Ⅱ diabetes mellitus a disease of innate immune system? Diabetologia,1998,41:1241-1248.
  • 4Grigsby RJ,Dobrowsky RT.Inhibition of ceramide productionreverses TNF-induced insulin resistance.Biochem Biophys Res Commun,2001,287:1121 1124.
  • 5朱禧星,潘长玉,李光伟,史虹莉,田慧,杨文英,姜晶,孙晓春,C.DAVIES,王梅,周永浩.磺酰脲类药物合用马来酸罗格列酮治疗2型糖尿病的有效性和安全性观察——随机、双盲、对照、平行、多中心临床试验[J].中华内分泌代谢杂志,2003,19(3). 被引量:36

共引文献26

同被引文献28

  • 1林青,孙璟,金翠燕,吴霖.罗格列酮对2型糖尿病病人血糖、血压、血脂的影响[J].中国新药与临床杂志,2004,23(12):871-873. 被引量:10
  • 2康志荣,黄建伟,刘群.2型糖尿病患者NO、ET、GMP-140水平测定的临床意义[J].天津医科大学学报,2005,11(3):483-484. 被引量:2
  • 3罗洁,曹丽.酒石酸罗格列酮对2型糖尿病患者颈动脉内膜中层厚度作用的分析[J].天津医科大学学报,2006,12(1):62-64. 被引量:2
  • 4张妍,徐桂芳,程雯,徐婷,陈淑雯.罗格列酮对2型糖尿病患者颈动脉内膜厚度的影响[J].中国临床药理学杂志,2007,23(3):168-170. 被引量:3
  • 5Perassolo MS, Almeida JC, Steemburgo T, et al. Endothelial dysfunction and serum fatty acid composition in patients with type 2 diabetes meUitus[ J]. Metabolism ,2008,57 (9) : 1167-1172.
  • 6Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature [ J ]. Circ Res, 2005,102 ( 3 ) : 283 -294.
  • 7Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis[J].irculation,2007, 115(4): 459-467.
  • 8Tunis SL, Minshall ME, St-Charles M, et al. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia : cost-effectiveness in the US. [J]. Curt Med Res Opin, 2008,24(11): 3085-3096.
  • 9Lin KD, Chang YH, Wang CL, et al. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea[J]. Transl Res, 2008, 151(6): 309-314.
  • 10Panunti B,Kunhiraman B,Fonseca V,et al. The impact of antidiabetic therapies on cardiovascular disease[J]. Curt Atheroscler Rep,2005, 7(1): 50-57.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部